Cargando…

A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?

Detalles Bibliográficos
Autores principales:	Troadec, E, Dobbelstein, S, Bertrand, P, Faumont, N, Trimoreau, F, Touati, M, Chauzeix, J, Petit, B, Bordessoule, D, Feuillard, J, Bastard, C, Gachard, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292680/ https://www.ncbi.nlm.nih.gov/pubmed/27795560 http://dx.doi.org/10.1038/leu.2016.304

Ejemplares similares

Colorectal adenomas and cancer link to chromosome 13q22.1-13q31.3 in a large family with excess colorectal cancer
por: Neklason, Deborah W, et al.
Publicado: (2010)

Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
por: Chen, Fangli, et al.
Publicado: (2016)

A Novel (Paternally Inherited) Duplication 13q31.3q32.3 in a 12-Year-Old Patient with Facial Dysmorphism and Developmental Delay
por: Atack, E., et al.
Publicado: (2014)

Clinical, Cytogenetic, and Biochemical Analyses of a Family with a t(3;13)(q26.2;p11.2): Further Delineation of 3q Duplication Syndrome
por: Abreu-González, M., et al.
Publicado: (2013)

Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying FLT3‐ITD with CN‐LOH at chr13q
por: Kim, TaeHyung, et al.
Publicado: (2022)

The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
por: Cueto, Francisco J., et al.
Publicado: (2021)

Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
por: Maiorova, Varvara, et al.
Publicado: (2023)

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
por: Lim, Sung Hee, et al.
Publicado: (2016)

Flt3 Ligand Regulates Dendritic Cell Development from Flt3(+) Lymphoid and Myeloid-committed Progenitors to Flt3(+) Dendritic Cells In Vivo
por: Karsunky, Holger, et al.
Publicado: (2003)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Maiorova, Varvara, et al.
Publicado: (2021)

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells
por: Ly, Bui Thi Kim, et al.
Publicado: (2013)

DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells
por: Wu, Min, et al.
Publicado: (2016)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia
por: Chauzeix, Jasmine, et al.
Publicado: (2020)

Long-term follow-up of a patient with 5q31.3 microdeletion syndrome and the smallest de novo 5q31.2q31.3 deletion involving PURA
por: Bonaglia, Maria Clara, et al.
Publicado: (2015)

FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors
por: Smith, Catherine C., et al.
Publicado: (2015)

Altered compensatory cytokine signaling underlies the discrepancy between Flt3(–/–) and Flt3l(–/–) mice
por: Durai, Vivek, et al.
Publicado: (2018)

Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics
por: Kellner, Fabienne, et al.
Publicado: (2020)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
por: Knight, Tristan E., et al.
Publicado: (2022)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
por: Othman, Jad, et al.
Publicado: (2023)

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase
por: Weisberg, Ellen L., et al.
Publicado: (2017)

FLT3 in lineage specification and plasticity
por: Greenblatt, Sarah, et al.
Publicado: (2012)

UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017)

FLT3 dancing on the stem cell
por: Levis, Mark
Publicado: (2017)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia
por: Jawhar, Mohamad, et al.
Publicado: (2017)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

Fast Maturation of Splenic Dendritic Cells Upon TBI Is Associated With FLT3/FLT3L Signaling
por: Zhang, Jin, et al.
Publicado: (2022)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
por: Wachholz, Vanessa, et al.
Publicado: (2021)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
por: Short, Nicholas J., et al.
Publicado: (2023)

Infantile spasms related to a 5q31.2-q31.3 microdeletion including PURA
por: Shimojima, Keiko, et al.
Publicado: (2018)

Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells
por: Weisberg, Ellen, et al.
Publicado: (2011)

Flt3/Flt3L Participates in the Process of Regulating Dendritic Cells and Regulatory T Cells in DSS-Induced Colitis
por: Mao, Jing-Wei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v84tp5jt92mnd81eukti8lmm11